Drug Trial News

RSS

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

QLT Inc. today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in pediatric patients with Leber Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

15 Dec 2009

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Update on new clinical developments and other initiatives related to Ceplene

EpiCept Corporation today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

ARIAD Pharmaceuticals, Inc. today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

The Microbicides Development Programme announced earlier today that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

Drug Trial News

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Molecular Partners closes its CHF 46 million Series B equity investment round

Update on new clinical developments and other initiatives related to Ceplene

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Combination therapy improves overall survival in women with advanced breast cancer

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Genentech announces positive results from Phase II study of T-DM1

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Positive interim results of ARRY-380 in Phase 1 trial announced

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News